SI2977385T1 - Humanizirana protitelesa specifična na protofibrilarno obliko peptida amiloid-beta - Google Patents
Humanizirana protitelesa specifična na protofibrilarno obliko peptida amiloid-beta Download PDFInfo
- Publication number
- SI2977385T1 SI2977385T1 SI201031662T SI201031662T SI2977385T1 SI 2977385 T1 SI2977385 T1 SI 2977385T1 SI 201031662 T SI201031662 T SI 201031662T SI 201031662 T SI201031662 T SI 201031662T SI 2977385 T1 SI2977385 T1 SI 2977385T1
- Authority
- SI
- Slovenia
- Prior art keywords
- seq
- sequence
- sequences
- antibody
- antibody according
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (20)
- Humanizirana protitelesa specifična na protofibrilamo obliko peptida amiloid-beta Patentni zahtevki1. Humanizirano protitelo specifično na protofibrilamo obliko peptida Α-β, značilno po tem, da: ima omenjeno protitelo zmanjšane efektorske funkcije, variabilni del njegove težke verige vsebuje zaporedje, ki je vsaj 90% enako z zaporedjem SEQ ID NO: 6 ali SEQ ID NO: 28, - variabilni del njegove lahke verige vsebuje zaporedje, kije vsaj 90% enako z zaporedjem SEQ ID NO: 8 ali SEQ ID NO: 24, - ima omenjeno protitelo afiniteto do protofibrilame oblike peptida Α-β vsaj 10 krat večjo od njegove afinitete do drugih oblik tega peptida, kjer je afiniteta EC50 merjena po postopku ELISA; in se omenjeno protitelo veže na peptide Α-β združene v senilne ploščice in ne na difuzne depozite peptidov Α-β.
- 2. Protitelo po zahtevku 1, značilno po tem, daje omenjeno protitelo imunoglobulin, ki nosi mutacije domene Fc, ki zmanjšuje njegovo afiniteto za receptorje imunskega sistema.
- 3. Protitelo po zahtevku 1 ali 2, značilno po tem, daje omenjeno protitelo imunoglobulin G 4, katerega domena Fc je bila izpostavljena mutacijam, ki zmanjšujejo efektorsko aktivnost.
- 4. Protitelo po kateremkoli predhodnem zahtevku, značilno po tem, da vsebuje vsaj eno CDR, ki ga kodira nukleotidno zaporedje, ki ima zaporedje enako enemu izmed zaporedij SEQ ID NO: 9, 11, 13, 15, 17 in 19 ali se po zaporedjih razlikuje za 1,2, 3, 4 ali 5 nukleotidov iz teh zaporedij.
- 5. Protitelo po kateremkoli predhodnem zahtevku, značilno po tem, da vsebuje vsaj eno CDR ki ima zaporedje enako enemu izmed zaporedij s SEQ ID NO: 10, 12, 14,16,18 in 20.
- 6. Protitelo po kateremkoli predhodnem zahtevku, značilno po tem, da vsebuje vsaj eno CDR, katerega zaporedje se razlikuje po eni ali dveh amino kislinah, v primeijavi z enim izmed zaporedij SEQ ID NO: 10,12,14,16, 18 in 20, dokler protitelo vzdržuje svojo vezavno specifičnost.
- 7. Protitelo po kateremkoli predhodnem zahtevku, značilno po tem, da vsebuje CDR-je, kijih kodirajo (i) nukleotidna zaporedja SEQ ID NO: 9, 11, 13,15, 17 in 19, (ii) nukleotidna zaporedja SEQ ID NO: 9,11,13, 31,17 in 19, (iii) nukleotidna zaporedja SEQ ID NO: 9, 11, 29, 31, 17 in 19, ali zaporedja, ki se od teh zaporedij razlikujejo po 1, 2, 3, 4 ali 5 nukleotidih.
- 8. Protitelo po kateremkoli predhodnem zahtevku, značilno po tem, da vsebuje CDR-je zaporedja SEQ ID NO: 10,12, 14, 16, 18 in 20, CDR-je zaporedja SEQ ID NO: 10, 12, 14, 32, 18 in 20 ali CDR-je zaporedja SEQ ID NO: 10, 12, 30, 32, 18 in 20.
- 9. Protitelo po kateremkoli predhodnem zahtevku, značilno po tem, da: - je variabilni del njegove težke verige kodiran z zaporedjem, ki je vsaj 80% enako enemu izmed zaporedij SEQ ID NO: 5 ali SEQ ID NO: 27, - je variabilni del njegove lahke verige kodiran z zaporedjem, kije vsaj 80% enako enemu izmed zaporedij SEQ ID NO: 7 ali SEQ ID NO: 23, vsebuje težko verigo, ki jo kodira zaporedje, ki je vsaj 80% enako enemu izmed nukleotidnih zaporedij SEQ ID NO: 1 in SEQ ID NO: 25 in/ali težko verigo, ki jo kodira zaporedje, kije vsaj 80% enako enemu izmed polipeptidnih zaporedij SEQ ID NO: 2 in SEQ ID NO: 26 in/ali - vsebuje lahko verigo, ki jo kodira zaporedje, ki je vsaj 80% enako enemu izmed nukleotidnih zaporedij SEQ ID NO: 3 in SEQ ID NO: 21 in/ali lahko verigo, ki jo kodira zaporedje, kije vsaj 80% enako enemu izmed polipeptidnih zaporedij SEQ ID NO: 4 in SEQ ID NO: 22.
- 10. Protitelo po kateremkoli predhodnem zahtevku, značilno po tem, da: - vsebuje zaporedja, ki jih kodirajo (i) nukleotidna zaporedja SEQ ID NO: 5 in 7, (ii) nukleotidna zaporedja SEQ ID NO: 5 in 23 ali (iii) nukleotidna zaporedja SEQ ID NO: 27 in 23 in/ali zaporedja, kijih kodirajo (i) nukleotidna zaporedja SEQ ID NO: 1 in 3, (ii) nukleotidna zaporedja SEQ ID NO: 1 in 21 ali (iii) nukleotidna zaporedja SEQ ID NO: 25 in 21 in/ali - njegovo zaporedje vsebuje zaporedja polipeptidov (i) SEQ ID NO: 6 in 8, (ii) SEQ ID NO: 6 in 24 ali (iii) SEQ ID NO: 28 in 24 in/ali zaporedja polipeptidov (i) SEQ ID NO: 2 in 4, (ii) SEQ ID NO: 2 in 22, (iii) SEQ ID NO: 26 in 22.
- 11. Protitelo po kateremkoli predhodnem zahtevku, značilno po tem, da povzroči redukcijo amiloidnih ploščic.
- 12. Protitelo po kateremkoli zahtevku od 1 do 11, za uporabo v zdravljenju bolezni povezanih z nevrodegenerativnimi motnjami.
- 13. Protitelo za uporabo po zahtevku 12 v zdravljenju Alzheimerjeve bolezni.
- 14. Farmacevtski sestavek, ki vsebuje protitelo po kateremkoli zahtevku od 1 do 11 in ekscipiente.
- 15. Celica, ki proizvaja protitelo po kateremkoli zahtevku od 1 do 11.
- 16. Postopek izdelave protitelesa po kateremkoli zahtevku od 1 do 11, značilen po tem, da obsega kultiviranje celic po zahtevku 15.
- 17. Protitelo po kateremkoli zahtevku od 1 do 11 za uporabo kot zdravilo.
- 18. Polinukleotid, ki izraža protitelo po kateremkoli zahtevku od 1 do 11, značilen po tem, da omenjeni polinukleotid kodira za polipeptid, ki je vsaj 90% enak z enim izmed zaporedij SEQ ID NOS: 2,4, 6, 8, 22, 24, 26 ali 28 ali ima zaporedje, ki je vsaj 90% enako z enim izmed zaporedij SEQ ID NOS: 1, 3, 5, 7, 21, 23, 25 ali 27.
- 19. Rekombinantni vektor, ki vsebuje nukleinsko kislino po zahtevku 18.
- 20. Gostiteljska celica, ki vsebuje vektor po zahtevku 19.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0953133A FR2945538B1 (fr) | 2009-05-12 | 2009-05-12 | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
| EP15160538.3A EP2977385B1 (fr) | 2009-05-12 | 2010-05-11 | Anticorps humanises spécifiques de la forme protofibrillaire du peptide béta-amyloide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2977385T1 true SI2977385T1 (sl) | 2018-05-31 |
Family
ID=41591699
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201031662T SI2977385T1 (sl) | 2009-05-12 | 2010-05-11 | Humanizirana protitelesa specifična na protofibrilarno obliko peptida amiloid-beta |
| SI201030968T SI2430049T1 (sl) | 2009-05-12 | 2010-05-11 | Humanizirana protitelesa specifična na proto fibrilarno obliko beta-amiolidnega peptide |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201030968T SI2430049T1 (sl) | 2009-05-12 | 2010-05-11 | Humanizirana protitelesa specifična na proto fibrilarno obliko beta-amiolidnega peptide |
Country Status (42)
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY158903A (en) | 2007-11-16 | 2016-11-30 | Univ Rockefeller | Antibodies specific for the protofibril form of beta-amyloid protein |
| AR085302A1 (es) * | 2011-02-24 | 2013-09-18 | Sanofi Sa | Metodo de produccion de anticuerpos sialilados |
| JP2013159596A (ja) * | 2012-02-08 | 2013-08-19 | Nihon Univ | β−アミロイド前駆体タンパク質のマイクロ凝集体に特異的なモノクローナル抗体 |
| CA2904357C (en) | 2013-03-15 | 2020-09-22 | Intrinsic Lifesciences Llc | Anti-hepcidin antibodies and uses thereof |
| CN107106679B (zh) | 2014-08-08 | 2022-07-26 | 艾利妥 | 抗trem2抗体及其使用方法 |
| US10323088B2 (en) | 2014-09-22 | 2019-06-18 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
| WO2016164637A1 (en) | 2015-04-07 | 2016-10-13 | Alector Llc | Anti-sortilin antibodies and methods of use thereof |
| US11136390B2 (en) | 2015-06-12 | 2021-10-05 | Alector Llc | Anti-CD33 antibodies and methods of use thereof |
| JP7497953B2 (ja) | 2015-06-12 | 2024-06-11 | アレクトル エルエルシー | 抗ｃｄ３３抗体及びその使用方法 |
| WO2017013599A1 (en) | 2015-07-21 | 2017-01-26 | Bioarctic Neuroscience Ab | Method for treatment of traumatic brain injury targeting aggregated peptides |
| JP7525980B2 (ja) | 2015-08-28 | 2024-07-31 | アレクトル エルエルシー | 抗Ｓｉｇｌｅｃ－７抗体及びその使用方法 |
| US20190330335A1 (en) | 2015-10-06 | 2019-10-31 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| WO2017075432A2 (en) | 2015-10-29 | 2017-05-04 | Alector Llc | Anti-siglec-9 antibodies and methods of use thereof |
| US11472877B2 (en) | 2016-03-04 | 2022-10-18 | Alector Llc | Anti-TREM1 antibodies and methods of use thereof |
| US11339209B2 (en) | 2016-11-14 | 2022-05-24 | Novartis Ag | Compositions, methods, and therapeutic uses related to fusogenic protein minion |
| EP3354278A1 (en) * | 2017-01-31 | 2018-08-01 | Sanofi | Neuronal cell protective effect of antibodies specific for the protofibrillar form of the beta-amyloid peptide |
| US11359014B2 (en) | 2017-05-16 | 2022-06-14 | Alector Llc | Anti-siglec-5 antibodies and methods of use thereof |
| CN117700548A (zh) | 2017-08-03 | 2024-03-15 | 艾利妥 | 抗cd33抗体及其使用方法 |
| JP2020533948A (ja) | 2017-08-03 | 2020-11-26 | アレクトル エルエルシー | 抗ｔｒｅｍ２抗体及びその使用方法 |
| CR20200566A (es) | 2018-05-25 | 2021-02-19 | Alector Llc | Anticuerpos anti-sirpa y metodos de utilización de los mismos |
| AR126019A1 (es) | 2018-05-30 | 2023-09-06 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| CN112512638A (zh) | 2018-06-08 | 2021-03-16 | 艾利妥 | 抗siglec-7抗体及其使用方法 |
| SI3618928T1 (sl) | 2018-07-13 | 2023-04-28 | Alector Llc | Protitelesa proti sortilinu in postopki za uporabo le-teh |
| EA202190183A1 (ru) | 2018-07-27 | 2021-05-18 | Алектор Ллс | Антитела к siglec-5 и способы их применения |
| SG11202101552SA (en) | 2018-08-31 | 2021-03-30 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
| UY38407A (es) | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
| TW202110878A (zh) | 2019-05-16 | 2021-03-16 | 法商賽諾菲公司 | 在神經系統中表現抗原結合蛋白 |
| CA3142513A1 (en) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
| US20220356233A1 (en) * | 2019-08-20 | 2022-11-10 | The Curators Of The University Of Missouri | Amyloid-beta antibodies |
| TW202124446A (zh) | 2019-09-18 | 2021-07-01 | 瑞士商諾華公司 | 與ｅｎｔｐｄ２抗體之組合療法 |
| EP4031578A1 (en) | 2019-09-18 | 2022-07-27 | Novartis AG | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
| JP2023506014A (ja) | 2019-12-12 | 2023-02-14 | アレクトル エルエルシー | 抗ｃｄ３３抗体の使用方法 |
| MX2023002194A (es) | 2020-08-25 | 2023-03-03 | Gilead Sciences Inc | Moleculas multiespecificas de union a antigenos dirigidas al vih y metodos de uso. |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法 |
| WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
| WO2023081898A1 (en) | 2021-11-08 | 2023-05-11 | Alector Llc | Soluble cd33 as a biomarker for anti-cd33 efficacy |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| US6136310A (en) | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
| US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| EP2082749A3 (en) | 2000-07-07 | 2010-06-30 | Bioarctic Neuroscience AB | Prevention and treatment of Alzheimer's disease |
| EP1366077B1 (en) * | 2000-09-15 | 2011-05-25 | Coley Pharmaceutical GmbH | PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST |
| TWI255272B (en) * | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| WO2005087177A2 (en) * | 2004-03-05 | 2005-09-22 | Ludwig Institute For Cancer Research | Chimeric anti-vegf-d antibodies and humanized anti-vegf-d antibodies and methods of using same |
| SE0401601D0 (sv) * | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| UA94019C2 (ru) * | 2004-07-09 | 2011-04-11 | Чугаи Сейяку Кабусики Кайся | Антитело, которое специфически связывается с глипиканом 3 (gpc3) |
| GEP20115195B (en) * | 2004-07-30 | 2011-04-11 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and use thereof |
| US7910100B2 (en) * | 2004-10-01 | 2011-03-22 | Max-Planck-Gesellschaft zur Forderung der Wissen | Antibodies directed to the mammalian EAG1 ion channel protein |
| CA2589860A1 (en) * | 2005-01-24 | 2006-08-03 | Amgen Inc. | Humanized anti-amyloid antibody |
| WO2007108755A1 (en) * | 2006-03-22 | 2007-09-27 | Gyros Patent Ab | Plex method |
| RU2429244C2 (ru) * | 2006-03-23 | 2011-09-20 | Байоарктик Ньюросайенс Аб | Улучшенные селективные в отношении протофибрилл антитела и их применение |
| HUE033325T2 (en) * | 2007-01-05 | 2017-11-28 | Univ Zuerich | Anti-beta-amyloid binder antibodies and their use |
| CA2676049C (en) * | 2007-03-01 | 2018-04-10 | Symphogen A/S | Recombinant anti-epidermal growth factor receptor antibody compositions |
| SG10201407388XA (en) | 2007-08-29 | 2015-01-29 | Sanofi Aventis | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses |
| MY158903A (en) * | 2007-11-16 | 2016-11-30 | Univ Rockefeller | Antibodies specific for the protofibril form of beta-amyloid protein |
| MX2010014319A (es) * | 2008-07-08 | 2011-05-19 | Geneuro Sa | Uso terapeutico de ligando especifico en enfermedades asociadas con msrv. |
| BRPI1009458A2 (pt) * | 2009-03-10 | 2016-03-01 | Baylor Res Inst | vacinas antivirais direcionadas às células de apresentação de antígeno |
| CN103415534A (zh) * | 2009-03-10 | 2013-11-27 | 贝勒研究院 | 靶向抗原呈递细胞的癌症疫苗 |
| TWI508976B (zh) * | 2009-04-21 | 2015-11-21 | Univ Rockefeller | 對β－類澱粉蛋白之基原纖維形式具專一性之抗體 |
-
2009
- 2009-05-12 FR FR0953133A patent/FR2945538B1/fr not_active Expired - Fee Related
-
2010
- 2010-05-11 MY MYPI2011005458A patent/MY159398A/en unknown
- 2010-05-11 SG SG2011085255A patent/SG176155A1/en unknown
- 2010-05-11 HU HUE15160538A patent/HUE036737T2/hu unknown
- 2010-05-11 MA MA34434A patent/MA33350B1/fr unknown
- 2010-05-11 TW TW105112498A patent/TWI583791B/zh not_active IP Right Cessation
- 2010-05-11 MX MX2011012060A patent/MX2011012060A/es active IP Right Grant
- 2010-05-11 EP EP16155574.3A patent/EP3050898B1/fr not_active Ceased
- 2010-05-11 LT LTEP15160538.3T patent/LT2977385T/lt unknown
- 2010-05-11 DK DK15160538.3T patent/DK2977385T3/en active
- 2010-05-11 ES ES15160538.3T patent/ES2664409T3/es active Active
- 2010-05-11 PT PT151605383T patent/PT2977385T/pt unknown
- 2010-05-11 EA EA201171388A patent/EA028357B1/ru not_active IP Right Cessation
- 2010-05-11 KR KR1020117029577A patent/KR101783058B1/ko active IP Right Grant
- 2010-05-11 SI SI201031662T patent/SI2977385T1/sl unknown
- 2010-05-11 TW TW099115013A patent/TWI542360B/zh not_active IP Right Cessation
- 2010-05-11 US US13/319,710 patent/US8614299B2/en active Active
- 2010-05-11 SI SI201030968T patent/SI2430049T1/sl unknown
- 2010-05-11 PT PT107287435T patent/PT2430049E/pt unknown
- 2010-05-11 JP JP2012510343A patent/JP2012526541A/ja active Pending
- 2010-05-11 UA UAA201114656A patent/UA107574C2/ru unknown
- 2010-05-11 BR BRPI1012853-0A patent/BRPI1012853B1/pt not_active IP Right Cessation
- 2010-05-11 EP EP10728743.5A patent/EP2430049B1/fr active Active
- 2010-05-11 RS RS20150459A patent/RS54122B1/en unknown
- 2010-05-11 DK DK10728743.5T patent/DK2430049T3/en active
- 2010-05-11 PL PL10728743T patent/PL2430049T3/pl unknown
- 2010-05-11 AR ARP100101602A patent/AR076670A1/es active IP Right Grant
- 2010-05-11 PE PE2011001949A patent/PE20120906A1/es active IP Right Grant
- 2010-05-11 AU AU2010247215A patent/AU2010247215B2/en not_active Ceased
- 2010-05-11 WO PCT/FR2010/050915 patent/WO2010130946A1/fr active Application Filing
- 2010-05-11 CA CA2761665A patent/CA2761665A1/fr not_active Abandoned
- 2010-05-11 ES ES10728743.5T patent/ES2542757T3/es active Active
- 2010-05-11 EP EP15160538.3A patent/EP2977385B1/fr not_active Not-in-force
- 2010-05-11 PL PL15160538T patent/PL2977385T3/pl unknown
- 2010-05-11 NZ NZ596540A patent/NZ596540A/xx not_active IP Right Cessation
- 2010-05-11 CN CN201080030434.6A patent/CN102459336B/zh not_active Expired - Fee Related
- 2010-05-12 UY UY0001032633A patent/UY32633A/es active IP Right Grant
-
2011
- 2011-11-08 CR CR20110585A patent/CR20110585A/es unknown
- 2011-11-08 GT GT201100283A patent/GT201100283A/es unknown
- 2011-11-09 IL IL216237A patent/IL216237B/en active IP Right Grant
- 2011-11-10 TN TNP2011000571A patent/TN2011000571A1/fr unknown
- 2011-11-11 CO CO11153627A patent/CO6460745A2/es active IP Right Grant
- 2011-11-11 SV SV2011004058A patent/SV2011004058A/es active IP Right Grant
- 2011-11-11 ZA ZA2011/08301A patent/ZA201108301B/en unknown
- 2011-11-11 NI NI201100195A patent/NI201100195A/es unknown
- 2011-11-11 CL CL2011002831A patent/CL2011002831A1/es unknown
- 2011-11-11 EC EC2011011452A patent/ECSP11011452A/es unknown
-
2012
- 2012-08-13 HK HK12107898.4A patent/HK1167152A1/xx not_active IP Right Cessation
-
2013
- 2013-10-01 US US14/042,942 patent/US9382312B2/en not_active Expired - Fee Related
-
2015
- 2015-07-14 CY CY20151100622T patent/CY1116842T1/el unknown
- 2015-07-14 HR HRP20150776TT patent/HRP20150776T1/hr unknown
- 2015-10-01 JP JP2015195617A patent/JP6310895B2/ja not_active Expired - Fee Related
-
2016
- 2016-06-02 US US15/171,708 patent/US10112991B2/en not_active Expired - Fee Related
-
2018
- 2018-03-27 HR HRP20180516TT patent/HRP20180516T1/hr unknown
- 2018-03-27 CY CY20181100343T patent/CY1120413T1/el unknown
- 2018-09-26 US US16/142,666 patent/US20190119365A1/en not_active Abandoned
- 2018-11-27 HR HRP20181985TT patent/HRP20181985T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2977385T1 (sl) | Humanizirana protitelesa specifična na protofibrilarno obliko peptida amiloid-beta | |
| JP6952827B2 (ja) | 血液脳関門輸送分子およびそれらの使用 | |
| CN110769851B (zh) | 兽用抗il31抗体 | |
| TWI585103B (zh) | 抗ｂａｆｆ抗ｉｌ－１７雙特異性抗體 | |
| HRP20150799T1 (hr) | Sastavi i postupci za protutijela protiv komplementnog proteina c5 | |
| CA2985985A1 (en) | Specific modification of antibody by igg-binding peptide | |
| FI3378535T3 (fi) | Alfa-synukleiinin tunnistavia humanisoituja vasta-aineita | |
| SI2481753T1 (sl) | Anti-IL-17 protitelesa | |
| ES2368764T3 (es) | ANTAGONISTAS SELECTIVOS DE huTNFR1. | |
| KR20240001331A (ko) | 신경병성 통증의 치료를 위한 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리의 용도 | |
| US10604586B2 (en) | Humanized monoclonal antibody and uses thereof | |
| WO2015191934A2 (en) | Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases | |
| RU2770209C2 (ru) | Терапевтические антитела против лиганда cd40 | |
| JP2016027801A (ja) | 改良された抗血清アルブミン結合変異体 | |
| BR112019013955A2 (pt) | Composições e métodos relacionados a construtos de fc manipulados | |
| JP2018525032A5 (sl) | ||
| CN115515635A (zh) | 兽用抗il4受体抗体 | |
| AU2019255270A1 (en) | Trivalent trispecific antibody constructs | |
| CA3186614A1 (en) | Anti-abeta antibodies | |
| KR20220027825A (ko) | 항-EphA4 항체 | |
| US20170129926A1 (en) | New Polypeptide | |
| EP2778173A1 (en) | Antibody directed against anthrax toxins and its uses | |
| RU2019123112A (ru) | Анти-il-5 антитела | |
| CN110267680B (zh) | 感染性疾病或炎症性疾病的预防和/或治疗剂 | |
| WO2018236728A1 (en) | ANTIBODIES AND ANTAGONISTS OF IL17A FOR VETERINARY USE |